No Data
No Data
Geron Corporation (NASDAQ:GERN) Is a Favorite Amongst Institutional Investors Who Own 72%
Needham Maintains Geron(GERN.US) With Buy Rating, Maintains Target Price $6
Sector Update: Health Care Stocks Steady Premarket Friday
Express News | Needham Reiterates Buy on Geron, Maintains $6 Price Target
Buy Rating on Geron Driven by EU Approval Prospects and Strategic Commercialization of Rytelo
Geron's Rytelo Secures European Medicines Agency Committee's Approval Recommendation